Impact of preceding respiratory viral infections on the clinical severity of patients with pneumococcal pneumonia

Young Kyung Yoon, a,b Kyung Sook Yang, c Jang Wook Sohn, a,b Chang Kyu Lee, d Min Ja Kim, a,b

*Division of Infectious Diseases, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea. bInstitute of Emerging Infectious Diseases, Korea University College of Medicine, Seoul, Korea. cDepartment of Biostatistics, Korea University College of Medicine, Seoul, Korea. dDepartment of Laboratory Medicine, Korea University College of Medicine, Seoul, Korea.

Correspondence: Min Ja Kim, Division of Infectious Diseases, Department of Internal Medicine, Korea University Anam Hospital, Korea University College of Medicine, 73, Inchon-ro, Seongbuk-gu, Seoul 136-705, Korea. E-mail: macropha@korea.ac.kr

Accepted 26 May 2014. Published Online 24 June 2014.

**Background** This study aimed to investigate the impact of preceding respiratory viral infections (RVI) on the clinical severity of pneumococcal pneumonia patients.

**Methods** A retrospective observational study was conducted at a university hospital from January 2009 to March 2013. Study subjects included adults (aged ≥18 years) with pneumococcal pneumonia who had undergone laboratory tests for RVI. Multivariate logistic regression analysis was performed to identify risk factors associated with severe pneumococcal pneumonia, defined as severity with the Pneumonia Severity Index (PSI) score ≥91.

**Results** In total, 191 patients with pneumococcal pneumonia were included for analysis and stratified into 2 groups: the severe group with a PSI score ≥91 (n = 99) and the non-severe group with a PSI score <91 (n = 92). Preceding RVIs were detected in 48 patients, including influenza A virus (n = 20), influenza B virus (n = 4), parainfluenza viruses (n = 5), metapneumovirus (n = 4), rhinovirus (n = 4), respiratory syncytial viruses (n = 6), coronaviruses (n = 2), and mixed viral infections (n = 3). In the multivariate logistic regression analysis, preceding RVIs (odds ratio [OR], 2.49; 95% confidence interval [CI], 1.10–5.60), male sex (OR, 2.58; 95% CI, 1.24–5.38), old age (OR, 2.92; 95% CI, 1.37–6.24), hypoalbuminemia (OR, 3.26; 95% CI, 1.56–6.84), and azotemia (OR, 2.24; 95% CI, 1.08–4.67) were significantly associated with severe pneumococcal pneumonia.

**Conclusion** This study suggests that preceding RVIs might be one of the risk factors affecting the clinical severity of pneumococcal pneumonia.

**Keywords** Clinical severity, pneumonia, respiratory viruses, *Streptococcus pneumoniae*.

Please cite this paper as: Yoon et al. (2014) Impact of preceding respiratory viral infections on the clinical severity of patients with pneumococcal pneumonia. Influenza and Other Respiratory Viruses 8(5), 549–556.

**Background** Community-acquired pneumonia (CAP) is the leading cause of death due to infectious diseases worldwide and accounts for major morbidity, mortality, and cost of care. 1,2 *Streptococcus pneumoniae* is the most dominant bacterial cause of CAP in adults. 3 Despite advances in medical care, mortality from pneumococcal pneumonia still ranges from 11% to 20%. 4,5 Known prognostic factors for mortality due to pneumococcal pneumonia include old age, male sex, pre-existing lung diseases, solid organ tumors, nosocomial infections, leukopenia, low body temperature, urea nitrogen level >30 mg/dl, hypoalbuminemia, hypoxemia, septic shock, and high severity scores. 6–9 However, preceding respiratory virus infection (RVI) as a potential risk factor for severe pneumococcal pneumonia was not evaluated in these studies due to the unavailability of routine virological diagnostic assays. 6–9 It has been observed that polymerase chain reaction (PCR)-based testing allows the detection of various respiratory viruses and viral–bacterial co-infection might be associated with severe diseases. 10–14

Rapid molecular diagnostic techniques, such as multiplexed nucleic acid PCR assays for respiratory viral pathogens, have recently been introduced into clinical practice. In recent studies, one or more respiratory virus infections have been reported in hospitalized adult patients with CAP. 10–12 Particularly, preceding RVIs have long been regarded as a predisposing factor for pneumococcal pneumonia. 12,15–18 Viral infections cause changes in respiratory tracts, including bronchoconstriction, increased mucus production, 19 stronger adhesion of pneumococci to virus-infected cells than uninfected cells, 20 decreased ciliary action, 21 damage to
mucosal cells, and dysfunction of leukocytes. However, studies regarding the clinical impact of preceding RVIs in patients with pneumococcal pneumonia are limited.

The purpose of this study was to evaluate the clinical significance of preceding RVIs on the clinical severity of pneumococcal pneumonia in adults.

Methods

Study design

This was a retrospective case-control study, which was performed at a 950-bed tertiary care hospital in Seoul, the Republic of Korea, from January 2009 to March 2013. Subjects included adult patients (age ≥18 years) with pneumococcal pneumonia who had been tested for RVI using multiplex reverse transcription-polymerase chain reaction (RT-PCR) within 30 days preceding S. pneumoniae isolation and were followed up until death or hospital discharge. A case was defined as a patient with severe pneumonia (i.e., PSI score ≥91 [risk class ≥IV]), while a control was defined as an adult patient with non-severe pneumonia (i.e., PSI score ≤90 [risk class ≤III]).

The study protocol was approved by the hospital institutional review board, which also waived the requirement of informed consent, as this retrospective study required no deviation from routine medical practice.

Definitions and data collection

Pneumococcal pneumonia was defined as an acute lower respiratory tract infection with opacity or infiltrates on a chest radiograph as confirmed by radiologists plus isolation of S. pneumoniae from sputum samples in outpatients or inpatients within 48 hours of hospital admission. All patients received antimicrobial therapy for >5 days. Acute lower respiratory tract infection was defined as the presence of two or more of the following symptoms or signs: productive cough, fever, dyspnea, pleuritic chest pain, and crackles. Septic shock was defined according to standard criteria.

Clinical data for each patient diagnosed with pneumococcal pneumonia were collected from a computerized hospital database. Only a single episode per patient was included in this study during all winter seasons. Patients who did not undergo laboratory tests for RVI within 30 days preceding pneumococcal pneumonia were excluded. Hospital-acquired pneumonia cases that were presented ≥48 hours after admission or within 7 days after hospital discharge were also excluded. All patients were treated with antibiotics according to local practice guidelines.

Clinical parameters for analysis included demographic and clinical characteristics, comorbid medical conditions, pneumonia treatment, antimicrobial susceptibility, and treatment outcome. The PSI and CURB-65 scores were calculated based on the clinical presentation of pneumonia. Pneumonia-related mortality was defined according to microbiological failure, persistent pneumonia-associated symptoms and signs, and the absence of other definite causes of death.

Microbiological methods

Blood and sputum cultures were routinely performed for patients who were present at the emergency room or were admitted to the hospital due to suspected pneumonia. Simultaneously, patients who had preceding or concurrent flu-like or cold symptoms underwent nasopharyngeal swab sampling to isolate the respiratory viruses. Clinical isolates of S. pneumoniae were identified by conventional biochemical methods and the VITEK 2 GP card (bioMérieux, Marcy l’Etoile, France). Antimicrobial susceptibility was determined using the VITEK 2 system according to the revised Clinical and Laboratory Standards Institute’s interpretive criteria for S. pneumoniae.

Nasopharyngeal swab samples were tested for 12 respiratory virus pathogens, including influenza virus type A and type B, human metapneumovirus (HMPV), respiratory syncytial virus (RSV) type A and type B, rhinovirus, parainfluenza viruses (PIV; types 1, 2, and 3), coronaviruses OC43/229E and NL63, and adenovirus, by using the Seeplex RV assay (Seegene, Inc., Seoul, Korea) based on a multiplex RT-PCR method. Viral DNA and RNA were extracted from each respiratory specimen using the Gene-spin™ kit (iNTRON Biotechnology, Seoul, Korea) according to the manufacturer’s instructions and the nucleic acid amplification was conducted using the Seeplex RV master mix as described previously.

Statistical analyses

Demographic and clinical characteristics were compared between patients with severe and non-severe pneumococcal pneumonia. Independent categorical variables were described using counts (proportions) and compared using the chi-square test or Fisher’s exact test. Continuous variables were expressed as mean ± standard deviation or median interquartile range (IQR). A two-sample Student’s t-test was used to compare continuous independent variables with normal distribution. A Mann–Whitney U-test was used to compare continuous independent variables with a non-normal distribution. Multivariate logistic regression analyses using a backward stepwise variable selection based on logistic regression statistics was used to examine the impact of multiple independent predictors on the clinical severity of pneumococcal pneumonia as a dependent variable. Hosmer–Lemeshow goodness-of-fit tests were performed to evaluate the models. Internal accuracy obtained by leave-one-out cross-validation was used to evaluate the performance of the predictive model. Statistical significance was defined as a
Results

Patients and clinical characteristics

During the study period, a total of 504,694 patients visited our hospital as outpatients (n = 410,856) or inpatients (n = 93,838). A total of 975 patients (1003 multiple episodes) who had S. pneumoniae isolation from sputum cultures were initially screened. Of these patients, 900 were aged ≥18 years. Patients who did not undergo multiplex RT-PCR for RVI within 30 days preceding S. pneumoniae isolation (n = 640), received antibiotic therapy for <5 days (n = 51), and acquired pneumonia at the hospital (n = 18) were excluded from the study. Finally, 191 patients who had pneumococcal pneumonia were analyzed for the study, including 26 (13-6%) outpatients and 165 (86-4%) hospitalized patients. None of them had polymicrobial infection or any simultaneous infections at other sites.

The median (IQR) of the CURB-65 and PSI scores in the 191 patients with pneumococcal pneumonia were 2 (1-4) and 92 (74-117), respectively. PSI classes were observed as follows: class II (n = 38, 19-9%), class III (n = 53, 27-7%), class IV (n = 71, 37-2%), and class V (n = 29, 15-2%). Ninety-nine (51-8%) patients had severe pneumococcal pneumonia (PSI score ≥91).

One hundred and thirty-two (66-3%) patients received RVI testing throughout the influenza seasons of the Northern hemisphere (November to April). Forty-eight (25-1%) patients had preceding or concurrent RVIs detected by multiplexed RT-PCR performed within 30 days of pneumonia presentation (Table 1). In particular, Influenza A and B and RSV infections were predominant during the winter months of the study period (January 2009 to March 2013) as shown in Figure 1.

Comparisons of demographic and clinical characteristics between the patients with severe and non-severe pneumococcal pneumonia are shown in Table 2. Hypoalbininemia, azotemia, and thrombocytopenia were more common in the case group (severe pneumococcal pneumonia) than in the control group (non-severe pneumococcal pneumonia). In addition, anemia and hyperbilirubinemia were more common in the case group (Table 2). The case group had more frequent preceding RVIs than the control group.

The case group had more multilobar consolidation on the chest radiographs than the control group (32 [32-3%] versus 15 [16-3], respectively; P = 0.010). However, there was no significant difference in the complicated pleural effusion between the case and control groups (8 [8-1%] versus 4 [4-3], respectively; P = 0.288).

Impact of preceding RVIs on clinical severity

In the multivariate logistic regression analysis, preceding RVI (odds ratio [OR], 2.49; 95% confidence interval [CI], 1.10–5.60), male sex (OR, 2.58; 95% CI, 1.24–5.38), old age (OR, 2.92; 95% CI, 1.37–6.24), hypoalbuminemia (OR, 3.26; 95%
CI, 1.56–6.84), and azotemia (OR, 2.24; 95% CI, 1.08–4.67) were significantly associated with severe pneumococcal pneumonia (Table 5). The P-values for the Hosmer–Leme-

show goodness-of-fit test were >0.05 (P = 0.107). Hence, there was no significant evidence of a lack of fit for any of the final models.
Impact of viral infections on pneumococcal pneumonia

Table 3. Antimicrobial treatment and clinical outcome in 191 patients with pneumococcal pneumonia according to clinical severity

| Variables                                      | All (n = 191) | Severe group (n = 99, 51.8%) | Non-severe group (n = 92, 48.2%) | P value |
|------------------------------------------------|---------------|------------------------------|---------------------------------|---------|
| Antiviral treatment (Oseltamivir), n (%)       | 17 (8.9)      | 11 (11.1)                    | 6 (6.5)                         | 0.266   |
| Antibiotic treatment, n (%)                    | 124 (64.9)    | 70 (70.7)                    | 54 (58.7)                       | 0.082   |
| Cephalosporins                                 | 4 (2.1)       | 1 (1.0)                      | 3 (3.3)                         | 0.353   |
| β-lactam/β-lactamase inhibitors                | 91 (47.6)     | 48 (48.5)                    | 43 (46.7)                       | 0.809   |
| Fluoroquinolones                               | 11 (5.8)      | 7 (7.1)                      | 4 (4.3)                         | 0.420   |
| Glycopeptides                                  | 12 (6.3)      | 8 (8.1)                      | 4 (4.3)                         | 0.288   |
| Macrolides                                     | 1 (1.0)       | 1 (1.0)                      | 1 (1.0)                         | 0.120   |
| Intensive care unit care                       | 1 (0.5)       | 3 (3.0)                      | 3 (3.2)                         | <0.001  |
| Mechanical ventilator care                     | 38 (20.2)     | 22 (22.2)                    | 7 (7.6)                         | 0.005   |
| Hemodialysis                                   | 0 (0.0)       | 2 (2.0)                      | 0 (0.0)                         | 0.498   |
| Hospital stay (day)*, median (IQR)             | 8 (4–18)      | 8 (6–17)                     | 6 (3–14)                        | 0.006   |
| Pneumococcal-related mortality, n (%)          | 12 (6.3%)     | 11 (11.1)                    | 1 (1.1)                         | 0.004   |
| In-hospital mortality, n (%)                   | 16 (8.4)      | 11 (11.1)                    | 5 (5.4)                         | 0.157   |

IQR, interquartile range.

<in-patient hospital days.>

Table 4. Antimicrobial resistance rates of Streptococcus pneumoniae isolates from 191 patients with pneumococcal pneumonia according to clinical severity

| Variables                                      | All (n = 191) | Severe group (n = 99, 51.8%) | Non-severe group (n = 92, 48.2%) | P value |
|------------------------------------------------|---------------|------------------------------|---------------------------------|---------|
| Penicillin                                     | 13 (6.8)      | 12 (12.1)                    | 1 (1.1)                         | 0.002   |
| Third generation cephalosporins                | 38 (19.9)     | 22 (22.2)                    | 16 (17.4)                       | 0.403   |
| Erythromycin                                   | 122 (63.9)    | 64 (64.6)                    | 58 (63.0)                       | 0.818   |
| Imipenem                                       | 15 (7.9)      | 12 (12.1)                    | 3 (3.3)                         | 0.023   |
| Levofloxacin                                   | 64 (33.5)     | 32 (32.3)                    | 32 (34.8)                       | 0.719   |
| TMP/SMX, trimethoprim/sulfamethoxazole.        | 105 (55.0)    | 53 (53.5)                    | 52 (56.5)                       | 0.679   |

Leone-one-out cross-validation was performed to assess the predictive accuracy of the final model. The AUCs for the clinical severity model were >0.80 for both the raw data set and the leave-one-out cross-validation. For the leave-one-out cross-validation, the sensitivity, specificity, positive predictive value, and negative predictive value obtained with an optimal cut-off point were >0.70 (Table 6).

During the study period, 142 adult patients with other forms of bacterial pneumonia underwent multiplex RT-PCR tests for RVI within 30 days preceding other types of bacterial isolation. Out of them, 25 (16.6%) patients had co-infection with RVIs and other forms of bacterial pneumonia, such as *Staphylococcus aureus* (n = 14), *Haemophilus influenzae* (n = 2), *Pseudomonas aeruginosa* (n = 3), and *Klebsiella pneumoniae* (n = 6). Preceding RVIs were detected in 25 patients, including influenza A virus (n = 9), HMPV (n = 2), rhinovirus (n = 8), RSV (n = 3), and mixed viral infections (n = 3: RSV plus coronavirus, coronavirus plus PIV, and rhinovirus plus PIV). In patients with preceding RVIs and other forms of bacterial pneumonia, compared to those with post-viral pneumococcal pneumonia, the median (IQR) of CURB-65 (2 [2–3] versus 2 [1–4], respectively; P = 0.720), PSI scores (118 [86–150] versus 100 [81–127], respectively; P = 0.201), severe pneumococcal pneumonia (10 [40–60%] versus 10 [20–80%], respectively; P = 0.081), all-cause in-hospital mortality rate (4 [16%] versus 4 [8.3%],
Preceding respiratory virus infection and those without preceding RVI. Not significantly different between patients with preceding RVIs on clinical severity. In previous studies, it was also reported that bacterial–viral co-infection in adults with CAP was associated with higher PSI risk than only bacterial infections. Hypoalbuminemia, azotemia, and host factors (i.e., male sex and increasing age) were also associated with the clinical severity of pneumococcal pneumonia, which are the known prognostic factors for mortality in patients with CAP. In this study, preceding RVIs was one of the independent risk factors associated with severe pneumococcal pneumonia (a higher PSI score ≥91), suggesting a potential role of preceding RVIs on clinical severity. In previous studies, it was also reported that bacterial–viral co-infection in adults with CAP was associated with higher PSI risk than only bacterial infections. Hypoalbuminemia, azotemia, and host factors (i.e., male sex and increasing age) were also associated with the clinical severity of pneumococcal pneumonia, which are the known prognostic factors for mortality in patients with CAP. For both outpatients (13.6%) and hospitalized patients (86.4%) in our study, the in-hospital mortality rate of pneumococcal pneumonia was 8.4% compared to 11–20% for only hospitalized patients from other studies. There was no mortality among the 26 outpatients, which included 2 (7.7%) patients with severe pneumonia. The in-hospital mortality rate (4 [8.3%] versus 12 [8.4%], respectively; P = 0.501) were not significantly different between patients with preceding RVIs and those without preceding RVI. In our study, the most frequent preceding RVI was influenza during the influenza season (November to April). Influenza virus infection has been demonstrated as an important predisposing factor for subsequent pneumococcal pneumonia.

Discussion

In this study, we investigated the impact of preceding RVIs on the clinical severity of pneumococcal pneumonia. Preceding RVIs, male sex, old age, hypoalbuminemia, and azotemia were identified as risk factors that were significantly associated with severe pneumococcal pneumonia (PSI score ≥91) through validation of a multivariate model designed to predict clinical severity.
pneumonia. The hypothesized synergistic interactions between the two pathogens includes epithelial damage, changes in airway function, up-regulation of receptors, and changes to innate immune response.\textsuperscript{19–21} While the seasonal distribution of preceding RSV and HMPV infections overlapped during the winter and spring periods, the PIV infections were distributed from June to August. Interactions between pneumococcus and other respiratory viruses have also been suggested. RSV-induced impairments of macrophage or neutrophil function and cytokine signaling have increased the risk for pneumococcal infections in the murine model.\textsuperscript{15,16} HMPV or PIV and pneumococcus co-infections have also been demonstrated to act synergistically in the mouse model.\textsuperscript{17,18}

During the study period, 25 (17.2\%) of the 142 patients with other forms of bacterial pneumonia had co-infection with RVIs: S. aureus (n = 14), H. influenzae (n = 2), P. aeruginosa (n = 3) and K. pneumoniae (n = 6). In contrast to pneumococcal pneumonia, preceding RVIs were not significantly associated with severe pneumonia in patients with other form of bacterial pneumonia.

According to our study, screening and early detection of RVIs in patients with severe pneumococcal pneumonia might be warranted for appropriate antiviral therapy and the prevention of intra-hospital transmission. Prevention strategies, including vaccination against both seasonal influenza and pneumococcal diseases, have already been emphasized during the influenza season.

Our study has certain limitations. First, this was a single-center study. The limited number of case subjects who underwent laboratory tests for RVI might be associated with selection bias. The multiplex RT-PCR test for respiratory viruses has been introduced into clinical practice recently. Therefore, many clinicians have still a low level of test awareness and only the patients who had preceding or concurrent flu-like or cold symptoms were chosen for RVI testing. Secondly, the number of patients with RVIs other than influenza limited the ability to determine how different viral pathogens affect the clinical severity of pneumococcal pneumonia. Thirdly, this retrospective observational study included patients with pneumococcal pneumonia who received antibiotic therapy for $\geq 5$ days based on the clinical diagnosis and outcome. Therefore, this study may not be representative of untreated patients of pneumococcal pneumonia. However, there were no patients who died within 5 days after admission among the 51 patients who had S. pneumoniae isolation from sputum cultures and received antibiotics therapy for $<5$ days. Fourthly, the incidence of pneumococcal bacteremia was low in our study; this might be partly due to the exposure of antibiotics before obtaining the first blood culture in 14 (7.3\%) patients or the study design, which included only patients with pneumococcal pneumonia who had virological tests for RVI prior to isolating pneumococci from sputum cultures.

**Conclusion**

In conclusion, preceding or concurrent RVIs might significantly influence the clinical severity in patients with pneumococcal pneumonia in addition to other factors, such as male sex, old age, hypoalbuminemia, and azotemia. Further studies are needed to understand the role of preceding or concurrent RVIs and to determine the clinical benefits of routine viral diagnostic tests for RVIs in patients with pneumococcal pneumonia.

**Funding**

This study was financially supported in part by Yuhan Co. (Seoul, Korea), the Korea University Grant (K1220811), the City of Seoul Grant #10920, and the National Research Foundation of Korea grant funded by the Korean government (No. K20902001448–10E0100–03010).

**Competing interests**

The authors declare that they have no competing interests.

**Author contributions**

Y.K.Y. analyzed the data and wrote the manuscript. C.K.L. and J.W.S. participated in the treatment of the patients. M.J.K. coordinated the study and revised the manuscript. All authors read and approved the final manuscript.

**References**

1. van der Poll T, Opal SM. Pathogenesis, treatment, and prevention of pneumococcal pneumonia. Lancet 2009; 374:1543–1556.
2. Lieberman D, Schlaeffer F, Baldur I et al. Multiple pathogens in adult patients admitted with community-acquired pneumonia: a one year prospective study of 346 consecutive patients. Thorax 1996; 51:179–784.
3. Woo JH, Kang JM, Kim YS et al. A prospective multicenter study of community-acquired pneumonia in adults with emphasis on bacterial etiology. Infect Chemother 2007; 33:1–7.
4. Feikin DR, Schuchat A, Kolczak M et al. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995–1997. Am J Public Health 2000; 90:223–229.
5. Rodriguez A, Lisboa T, Blot S et al. Mortality in ICU patients with bacterial community-acquired pneumonia: when antibiotics are not enough. Intensive Care Med 2009; 35:430–438.
6. Saldías PF, Viviani GP, Pulgar BD et al. Prognostic factors and mortality in immunocompetent adult patients hospitalized with community-acquired pneumococcal pneumonia. Rev Med Chil 2009; 137:1545–1552.
7. Song JS, Choe PG, Song KH et al. Risk factors for 30-day mortality in adult patients with pneumococcal bacteraemia, and the impact of
antimicrobial resistance on clinical outcomes. Epidemiol Infect 2012; 140:1267–1276.

8 Harboe ZB, Thomsen RW, Riis A et al. Pneumococcal serotypes and mortality following invasive pneumococcal disease: a population-based cohort study. PLoS Med 2009; 6:e1000081.

9 Riquelme R, Torres A, El-Ebiary M et al. Community-acquired pneumonia in the elderly: A multivariate analysis of risk and prognostic factors. Am J Respir Crit Care Med 1996; 154:1450–1455.

10 Johnstone J, Majumdar SR, Fox JD et al. Viral infection in adults hospitalized with community-acquired pneumonia: prevalence, pathogens, and presentation. Chest 2008; 134:1141–1148.

11 Templeton KE, Scheltinga SA, van den Eeden WC et al. Improved diagnosis of the etiology of community-acquired pneumonia with real-time polymerase chain reaction. Clin Infect Dis 2005; 41:345–351.

12 Jennings LC, Anderson TP, Beynon KA et al. Incidence and characteristics of viral community-acquired pneumonia in adults. Thorax 2008; 63:42–48.

13 Johansson N, Kalin M, Hedlund J. Clinical impact of combined viral and bacterial infection in patients with community-acquired pneumonia. Scand J Infect Dis 2011; 43:609–615.

14 Gaydos CA. What is the role of newer molecular tests in the management of CAP? Infect Dis Clin North Am 2013; 27:49–69.

15 Serft AP, Taylor RH, Lei W et al. Respiratory syncytial virus impairs macrophage IFN-alpha/beta- and IFN-gamma-stimulated transcription by distinct mechanisms. Am J Respir Cell Mol Biol 2010; 42:404–414.

16 Stark JM, Stark MA, Colasurdo GN et al. Decreased bacterial clearance from the lungs of mice following primary respiratory syncytial virus infection. J Med Virol 2006; 78:829–838.

17 Kukavica-Ibrulj I, Hamelin ME, Prince GA et al. Infection with human metapneumovirus predisposes mice to severe pneumococcal pneumonia. J Virol 2009; 83:1341–1349.

18 Alymova IV, Portner A, Takimoto T et al. The novel parainfluenza virus hemagglutinin-neuraminidase inhibitor BCX 2798 prevents lethal synergism between a paramyxovirus and Streptococcus pneumoniae. Antimicrob Agents Chemother 2005; 49:398–405.

19 Nickerson CL, Jakab GJ. Pulmonary antibacterial defenses during mild and severe influenza virus infection. Infect Immun 1990; 58:2809–2814.

20 Hament JM, Kimpen JL, Fleer A et al. Respiratory viral infection predisposing for bacterial disease: a concise review. FEMS Immunol Med Microbiol 1999; 26:189–195.

21 Tristram DA, Hicks W Jr, Hard R. Respiratory syncytial virus and human bronchial epithelium. Arch Otolaryngol Head Neck Surg 1998; 124:777–783.

22 Fine MJ, Auble TE, Yealy DM et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 336:243–250.

23 Longo DL, Fauci AS, Kasper DL et al. Harrison’s Principles of Internal Medicine, 18th edn. New York: McGraw-Hill, 2008.

24 Song JH, Jung KS, Kang MW et al. Treatment guidelines for community-acquired pneumonia in Korea: an evidence-based approach to appropriate antimicrobial therapy. Infect Chemother 2009; 41:133–153.

25 Charlson M, Szatrowski TP, Peterson J et al. Validation of a combined comorbidity index. J Clin Epidemiol 1994; 47:1245–1251.

26 Lim WS, van der Eeden MM, Laing R et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003; 58:377–382.

27 Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Eighteenth informational supplement, M100-S18. Wayne, PA: Clinical and Laboratory Standards Institute, 2008.

28 Roh KH, Kim J, Nam MH et al. Comparison of the Seeplex reverse transcription PCR assay with the R-mix viral culture and immunofluorescence techniques for detection of eight respiratory viruses. Ann Clin Lab Sci 2008; 38:41–46.